Oremus M, Wolfson C, Perrault A, Demers L, Momoli F, Moride Y
Center for Clinical Epidemiology and Community Studies, S.M.B.D. Jewish General Hospital, Montreal, Canada.
Dement Geriatr Cogn Disord. 2001 May-Jun;12(3):232-6. doi: 10.1159/000051263.
Drug therapies for Alzheimer's disease (AD) have been evaluated in clinical trials over the past 2 decades. Systematic reviews of AD drug trials can shed more light on the efficacy of pharmaceutical interventions. The modified Jadad scale can be used to assess the quality of trial reports that are candidates for inclusion in these systematic reviews. The interrater reliability of the modified Jadad scale was examined during such a review. Three blinded reviewers rated the quality of 42 AD drug trial reports: the intraclass correlation coefficient was 0.90. The modified Jadad scale appears to be a useful tool for AD research because of the very good interrater reliability. Also, it is composed of items that are well suited to the specific disease characteristics of AD. Further research should focus on the validity of this instrument.
在过去20年中，针对阿尔茨海默病（AD）的药物疗法已在临床试验中得到评估。对AD药物试验的系统评价可以更清楚地了解药物干预的疗效。改良的 Jadad 量表可用于评估这些系统评价中可能纳入的试验报告的质量。在这样一项评价中，对改良 Jadad 量表的评分者间信度进行了检验。三位盲法评审员对42份AD药物试验报告的质量进行了评分：组内相关系数为0.90。由于评分者间信度非常好，改良的 Jadad 量表似乎是AD研究的一个有用工具。此外，它由非常适合AD特定疾病特征的项目组成。进一步的研究应聚焦于该工具的效度。
